Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDiazoxide is an antihypertensive, activates ATP-dependent K+ channels (Kir6). Induces activation of PKCε, an intermediate in the opening of mitoKATP channels, results in cardioprotection against hypoxia-induced death. Blocks desensitization of AMPA receptors.
Diazoxide is also offered as part of the Tocriscreen FDA-Approved Drugs. 了解 Tocris 化合物库的更多信息。
分子量 | 230.67 |
公式 | C8H7ClN2O2S |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 364-98-7 |
PubChem ID | 3019 |
InChI Key | GDLBFKVLRPITMI-UHFFFAOYSA-N |
Smiles | CC1=NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 23.07 | 100 |
以下数据基于产品分子量 230.67。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 4.34 mL | 21.68 mL | 43.35 mL |
5 mM | 0.87 mL | 4.34 mL | 8.67 mL |
10 mM | 0.43 mL | 2.17 mL | 4.34 mL |
50 mM | 0.09 mL | 0.43 mL | 0.87 mL |
参考文献是支持产品生物活性的出版物。
Kim et al (2006) Dox acts more as a PKC-ε activator, and indirectly activates the mitochondiral KATP channel conferring cardioprotection against hypoxic injury. Br.J.Pharmacol. 149 1059 PMID: 17043673
Trube et al (1986) Opposite effects of tolbut. and Dox on the ATP-dependent K+ channel in mouse pancreatic β-cells. Pflugers Arch. 407 493 PMID: 2431383
Yamada and Rothman (1992) Dox blocks glutamate desensitization and prolongs excitatory postsynaptic currents in rat hippocampal neurons. J.Physiol. 458 409 PMID: 1302270
Merck Index 12 3051
If you know of a relevant reference for Diazoxide, please let us know.
关键词: Diazoxide, Diazoxide supplier, Blocks, desensitization, desensitisation, AMPA, receptors, K+, channel, opener, KATP, Glutamate, Receptors, iGlur, Ionotropic, Potassium, KIR, Kir6, Channels, Inward, Rectifier, rectifier, 0964, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Diazoxide 的部分引用包括:
Cox et al (2014) Chronic neonatal Dox therapy is not associated with adverse effects J Neurosci 14 49 PMID: 25587244
Niu et al (2011) Sex differences in the contribution of ATP-sensitive K+ channels in trigeminal ganglia under an acute muscle pain condition. Neuroscience 180 344 PMID: 21296645
Frazão et al (2013) Shift in Kiss1 cell activity requires estrogen receptor α. J Neurosci 33 2807 PMID: 23407940
Sun et al (2014) Label-free cell phenotypic profiling decodes the composition and signaling of an endogenous ATP-sensitive potassium channel. Sci Rep 4 4934 PMID: 24816792
您是否知道使用了 Tocris Diazoxide 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review Diazoxide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.